AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy

122Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We have recently shown that in diabetic OVE26 mice (type I diabetes), the AMP-activated protein kinase (AMPK) is reduced along with cardiac dysfunction and decreased cardiac autophagy. Genetic inhibition of AMPK in cardiomyocytes attenuates cardiac autophagy, exacerbates cardiac dysfunction and increases mortality in diabetic mice. More importantly, we have found chronic AMPK activation with metformin, one of the most used antidiabetes drugs and a well-characterized AMPK activator, significantly enhances autophagic activity, preserves cardiac function and prevents most of the primary characteristics of diabetic cardiomyopathy in OVE26 mice, but not in dominant negative-AMPK diabetic mice. We conclude that AMPK activation protects cardiac structure and function by increasing cardiac autophagy in the diabetic heart. © 2011 Landes Bioscience.

Cite

CITATION STYLE

APA

Xie, Z., He, C., & Zou, M. H. (2011). AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy. Autophagy, 7(10), 1254–1255. https://doi.org/10.4161/auto.7.10.16740

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free